Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Non-Current Assets (2022 - 2025)

Stoke Therapeutics has reported Non-Current Assets over the past 4 years, most recently at $112.7 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $112.7 million for Q4 2025, up 190.56% from a year ago — trailing twelve months through Dec 2025 was $346.3 million (up 242.23% YoY), and the annual figure for FY2025 was $112.7 million, up 190.56%.
  • Non-Current Assets for Q4 2025 was $112.7 million at Stoke Therapeutics, up from $87.8 million in the prior quarter.
  • Over the last five years, Non-Current Assets for STOK hit a ceiling of $114.5 million in Q2 2025 and a floor of $9.9 million in Q3 2023.
  • Median Non-Current Assets over the past 4 years was $12.6 million (2022), compared with a mean of $33.8 million.
  • Biggest five-year swings in Non-Current Assets: decreased 24.22% in 2023 and later surged 964.18% in 2025.
  • Stoke Therapeutics' Non-Current Assets stood at $12.0 million in 2022, then increased by 8.39% to $13.0 million in 2023, then soared by 198.38% to $38.8 million in 2024, then skyrocketed by 190.56% to $112.7 million in 2025.
  • The last three reported values for Non-Current Assets were $112.7 million (Q4 2025), $87.8 million (Q3 2025), and $114.5 million (Q2 2025) per Business Quant data.